Antonella Borgatti, DVM, MS, Dipl. ACVIM (Oncology), Dipl. ECVIM-CA

Associate Professor, Department of Veterinary Clinical Sciences

Antonella Borgatti

Contact Info

borgatti@umn.edu

Office Address:
1352 Boyd Avenue
St. Paul, MN 55108

Associate Professor, Department of Veterinary Clinical Sciences

College of Veterinary Medicine


Residency in Comparative Oncology, Purdue University, 2006

Research Associate Post Doctorate – Intern in Oncology, North Carolina State University, 2002

Research Scholar Associate Post Doctorate, North Carolina State University, 1999 – 2000

Educational Commission for Foreign Veterinary Graduates Certification, North Carolina State University, completed requirements in 2003

DVM, Graduated cum laude, University of Torino, Italy, 1996

Master of Sciences Degree in Veterinary Clinical Sciences, Purdue University, 2006

Diplomate of the American College of Veterinary Internal Medicine (Oncology) since 2006

Diplomate of the European College of Veterinary Internal Medicine (Oncology) since 2007

Summary

Dr. Borgatti graduated cum laude from the University of Torino, Italy in 1996. After three years in general practice, she received a scholarship to pursue specialized training in oncology at North Carolina State University where she subsequently remained as a Research Associate, Oncology Intern, and Clinical Instructor in Oncology. She completed a Residency in Comparative Oncology at Purdue University where she also received a Master of Sciences Degree in 2006. Dr. Borgatti became a Diplomate of the American College of Veterinary Internal Medicine (Oncology) in 2006 and a Diplomate of the European College of Veterinary Internal Medicine in 2007. She worked at a specialty referral hospital in North Carolina for two years before joining the faculty at the University of Minnesota in 2008. She is currently Associate Professor of Oncology in the College of Veterinary Medicine, Member of the Masonic Cancer Center, Member of the Vallera laboratory, and Director of the Oncology residency program.

Awards & Recognition

  • One-year scholarship from the University of Torino to gain specialized training in small animal oncology at North Carolina State University, College of Veterinary Medicine, 1999
  • Omicron Chapter of Phi Zeta Honor Society of Veterinary Medicine, elected to membership.
  • Excellence in course coordination award.

Professional Associations

  • Phi Zeta Honor Society of Veterinary Medicine
  • Veterinary Cancer Society
  • European College of Veterinary Internal Medicine
  • American College of Veterinary Internal Medicine
  • Masonic Cancer Center

Research

Research Summary/Interests

Dr. Borgatti is primarily interested in the clinical application of novel targeted therapeutics and immunotherapy approaches. Her recent work has focused on testing a novel, genetically engineered biological drug against chemotherapy refractory hemangiosarcoma in companion dogs with spontaneously arising cancer. The data generated by this work provided a strong rationale for translation to human clinical trial. As a member of the Vallera laboratory, Dr. Borgatti is also interested in strategies to engage the immune system to selectively kill cancer cells. 

Research Funding Grants

4/15/15 – 4/14/17 (PI: Borgatti) National Canine Cancer Foundation Preclinical evaluation and clinical translation of novel bispecific ligand targeted toxins for the treatment of sarcomas.

06/01/14 – 05/31/19 (PI: Borgatti) NIH K01 OD017242 Mentored Career Development Award

Publications

  1. Borgatti A, Koopmeiners JS, Sarver AL, WinterAL, StuebnerK, TodhunterD, RizzardiAE, HenriksenJC, SchmechelS, ForsterCL, KimJ, FroelichJ, WalzJ, HensonMS, BreenM, Lindblad-TohK, OhF, PilbeamK, ModianoJF, ValleraDV. Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR. Accepted for publication in Molecular Cancer Therapeutics.
  2. Fritz S, Henson M, Greengard E, Winter A, Stuebner K, Yoon U, Borgatti A, Wilke V, Augustin L, Modiano JF, Saltzman D. A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma. Veterinary Medicine and Science 2016 DOI:10.1002/vms3.32.
  3. Saba C, Paoloni M, Mazcko C, Kisseberth W, Burton JH, Smith A, Wilson-Robles H, Allstadt S, Vail D, Henry C, Lana S, Ehrhart EJ, Charles B, Kent M, Lawrence J, Burgess K, Borgatti A, Suter S, Woods P, Gordon I, Vrignaud P, Khanna C, LeBlanc A. A Comparative Oncology Study of Iniparib Defines its Pharmacokinetic Profile and Biological Activity in a Naturally-occurring Canine Cancer Model. PLOs ONE 2016. http://dx.doi.org/10.1371/journal.pone.0149194
  4. Cannon C, Knudson K, Borgatti A. Presentation, treatment, and outcome in cats with myeloma-related disorders. Journal Am Anim Hosp Assoc, 2015; 51(4):239-48. doi: 10.5326/JAAHA-MS-6216.
  5. London CA, Gardner HL, Mathie T, Stingle N, Portela R, Pennell ML, Clifford CA, Rosenberg MP, Vail DM, Williams LE, Cronin KL, Wilson-Robles H, Borgatti A, Henry CJ, Bailey DB, Locke J, Northrup NC, Crawford-Jakubiak M, Gill VL, Klein MK, Ruslander DM, Thamm DH, Phillips B, Post G.Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLoS One. 2015 Apr 29;10(4):e0124889. doi: 10.1371/journal.pone.0124889. eCollection 2015.
  6. Cannon C, Borgatti A, Henson M, Husbands B. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. J Small Anim Pract. 2015 Jul;56(7):425-9. doi: 10.1111/jsap.12354. Epub 2015 Apr 1.
  7. Ito D, Childress M, Mason N, Winter A, O’Brien T, Henson M, Borgatti A, Lewellen M, Krick E, Stewart J, Lahrman S, Leary J, Seelig D, Koopmeiners J, Ruetz S, Modiano J. A double blinded, placebo-controlled pilot study to examine reduction of CD34+/CD117+/CD133+ lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma [version 1; referees: 1 approved with reservations, 1 not approved].F1000Research2015,4:42 (doi:10.12688/f1000research.6055.1)
  8. London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson MS, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin J, McCauley D, Kauffman M, Shacham S.Preclinical Evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLOS one.2014DOI: 10.1371/journal.pone.0087585
  9. Borgatti A, Duckett M, Spangler C, Modiano JF. Binding of VEGF-A to canine cancer cells with preferential expression of VEGFR1, Vet World. 2013 7(1): 1-6, 2013.
  10. Feeney A, Sharkey L, Steward SM, Bahr KL, Henson MS, Ito D, O’Brien TD, Jessen CR, Husbands BD, Borgatti A, Modiano J. Applicability of 3T body MRI in assessment of non-focal bone marrow involvement from hematopoietic neoplasia in a spontaneous canine model. J Vet Intern Med. 2013 Sep-Oct; 27(5):1165-71
  11. Feeney A, Sharkey L, Steward SM, Bahr KL, Henson MS, Ito D, O’Brien TD, Jessen CR, Husbands BD, Borgatti A, Modiano J. Parenchymal organ signal intensity in 3T body MRI of canine hematopoietic neoplasia: a pilot animal model study. Comp Med. 2013 Apr; 63(2):174-82.
  12. Frantz AM, Sarver AL, Ito D, Phang TL, Karimpour-Fard A, Scott MC, Valli VEO, Lindblad-Toh K, Burgess KE, Husbands BD, Henson MS, Borgatti A, Kisseberth WC, Hunter LE, Breen M, O’Brien TD, Modiano JF. Molecular profiling reveals prognostically significant subtypes of canine lymphoma. Veterinary Pathology. 2013 (http://vet.sagepub.com/content/early/2013/02/19/0300985812465325)
  13. Ito D, Endicott MM, Jubala CM, Helm KM, Husbands BD, Borgatti A, Henson MS, Burgess KE, Bell JS, Kisseberth WC, Valli VE, Cutter GC, Hahn KA, O’Brien TD, Modiano JF. A Lymphoid Progenitor Population Inversely Correlated with Outcome in Canine non-Hodgkin Lymphoma. J Vet Intern Med. 2011 Jul: 25(4):890-896.
  14. Borgatti A & Buracco P. Un legame che va oltre l’amicizia: cane, uomo, ed oncologia comparata. Veterinaria. 2009 23(2).
  15. Dhawan D, Borgatti-Jeffreys A, Zheng R, Stewart JC, Knapp DW. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Therapeutics. 2008 Apr 7(4): 897-904.
  16. Borgatti-Jeffreys A, Hooser SB, Miller MA, Thomas RM, deGortari A, Lucroy MD. A Candidate Second-Generation Photosensitizer for Photodynamic Therapy in Veterinary Medicine. Am J of Vet Res. 2007 Apr; 68 (4): 399-404.
  17. Greenberg CB, Boria P, Borgatti-Jeffreys A, Raskin RE, Lucroy MD. Phase II Clinical Trial of Combination Chemotherapy with Dexamethasone for Lymphoma in Dogs. J Am Anim Hosp Assoc. 2007; 4: 27-32.
  18. Borgatti-Jeffreys A, Knapp DW, Carlton WW, Thomas RM, Bonney PL, deGortari A, Lucroy MD. Influence of Asparaginase on a Combination Chemotherapy Protocol for Canine Multicentric Lymphoma. J Am Anim Hosp Assoc. 2005 Jul-Aug; 41 (4): 221-6.

Teaching

Academic Interests and Focus

Dr. Borgatti teaches in the Small Animal Medicine III course (CVM 6594) where her didactic instructional areas include bone tumors, soft tissue sarcomas, and paraneoplastic syndromes. She also instructs for the Clinical Skills course. She really enjoys clinical teaching with students, interns and residents involved in the Clinical Comparative Oncology rotation (CVM 6648) within the Veterinary Teaching Hospital, Oncology service.

Clinical

Board Certifications

  • Diplomate of the American College of Veterinary Internal Medicine (Oncology)
  • Diplomate of the European College of Veterinary Internal Medicine (Oncology)

Clinical Interests

Small animal clinical oncology, comparative oncology, targeted therapeutics, immunotherapy.